Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...
Zacks Investment Research on MSN
Is TEM stock a buy, hold, or sell during its pivotal transition?
Tempus AI TEM is transitioning from a heavy-investment growth stage toward improved operating leverage and a more scalable ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...
Zacks.com on MSN
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn ...
Tempus AI stock is showing a mixed technical picture, with a moderately bearish trend and ongoing selling pressure, indicating potential downside risk. The stock, at $69.85, sits well below its ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...
Hosted on MSN
Tempus AI (TEM) Launches AI-Powered Whole-Genome Sequencing Test to Transform Precision Medicine
We recently published a list of 15 Important AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against other important ...
Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; ...
Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...
Tempus AI has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback